PHASE II TRIAL OF EMD 121974 FOR RECURRENT GLIOBLASTOMA

EMD 121974 治疗复发性胶质母细胞瘤的 II 期试验

• 批准号: 7607531
• 负责人: MINESH P. MEHTA
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607531
• 关键词: Blood flow; Cilengitide; Computer Retrieval of Information on Scientific Projects Database; EMD 121974 (Cilengitide); Funding; Glioblastoma; Grant; Growth; Institution; Operative Surgical Procedures; Patients; Phase II Clinical Trials; Recurrence; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Work; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov) Cilengitide (EMD 121974) may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Giving cilengitide before and after surgery may be an effective treatment for glioblastoma multiforme. This Phase II trial is studying how well cilengitide works in treating patients who are undergoing surgery for recurrent or progressive glioblastoma multiforme.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 （摘自ClinicalTrials.gov） Cilengitide（EMD 121974）可以通过阻断流向肿瘤的血液来阻止多形胶质母细胞瘤的生长。在手术前后，给出纤毛肽可能是多形胶质母细胞瘤的有效治疗方法。 这项II期试验正在研究Cilengitide在治疗正在接受复发或进行性胶质母细胞瘤多种形式的手术的患者方面的工作效果。